Veracyte Past Earnings Performance
Past criteria checks 2/6
Veracyte has been growing earnings at an average annual rate of 15.2%, while the Biotechs industry saw earnings growing at 15.2% annually. Revenues have been growing at an average rate of 27.8% per year. Veracyte's return on equity is 2.8%, and it has net margins of 7.1%.
Key information
15.21%
Earnings growth rate
20.65%
EPS growth rate
| Biotechs Industry Growth | 17.04% |
| Revenue growth rate | 27.78% |
| Return on equity | 2.77% |
| Net Margin | 7.13% |
| Last Earnings Update | 31 Mar 2025 |
Recent past performance updates
Recent updates
Veracyte, Inc.'s (NASDAQ:VCYT) Shares Lagging The Industry But So Is The Business
Jun 15
Veracyte: Upgrading To Neutral
May 26Veracyte, Inc. Just Beat EPS By 260%: Here's What Analysts Think Will Happen Next
May 10
Decipher, Afirma And MRD Tests Will Broaden Future Markets
Veracyte’s Decipher test expansion and updated NCCN guidelines could drive significant revenue growth and market share in the prostate cancer segment.Shareholders Can Be Confident That Veracyte's (NASDAQ:VCYT) Earnings Are High Quality
Mar 08Veracyte, Inc. (NASDAQ:VCYT) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough
Mar 04Veracyte, Inc.'s (NASDAQ:VCYT) Intrinsic Value Is Potentially 50% Above Its Share Price
Jan 09Veracyte: Getting Frothy
Dec 11Veracyte, Inc. (NASDAQ:VCYT) Surges 25% Yet Its Low P/S Is No Reason For Excitement
Dec 01Veracyte, Inc.'s (NASDAQ:VCYT) Price Is Right But Growth Is Lacking After Shares Rocket 42%
Aug 18Veracyte, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aug 09Veracyte, Inc.'s (NASDAQ:VCYT) Intrinsic Value Is Potentially 76% Above Its Share Price
Jul 02Veracyte, Inc.'s (NASDAQ:VCYT) Price Is Right But Growth Is Lacking
Jun 06Veracyte, Inc. (NASDAQ:VCYT) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
May 09Lacklustre Performance Is Driving Veracyte, Inc.'s (NASDAQ:VCYT) Low P/S
Apr 18A Look At The Intrinsic Value Of Veracyte, Inc. (NASDAQ:VCYT)
Mar 18Revenue & Expenses Breakdown
How Veracyte makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 25 | 463 | 33 | 202 | 71 |
| 31 Dec 24 | 446 | 24 | 199 | 69 |
| 30 Sep 24 | 425 | -9 | 202 | 69 |
| 30 Jun 24 | 400 | -54 | 200 | 64 |
| 31 Mar 24 | 375 | -68 | 195 | 73 |
| 31 Dec 23 | 361 | -74 | 193 | 57 |
| 30 Sep 23 | 343 | -50 | 186 | 50 |
| 30 Jun 23 | 329 | -29 | 184 | 47 |
| 31 Mar 23 | 311 | -30 | 174 | 41 |
| 31 Dec 22 | 297 | -37 | 171 | 41 |
| 30 Sep 22 | 284 | -43 | 187 | 40 |
| 30 Jun 22 | 268 | -49 | 177 | 37 |
| 31 Mar 22 | 251 | -48 | 171 | 30 |
| 31 Dec 21 | 220 | -76 | 180 | 30 |
| 30 Sep 21 | 187 | -73 | 119 | 24 |
| 30 Jun 21 | 157 | -63 | 105 | 20 |
| 31 Mar 21 | 123 | -65 | 89 | 17 |
| 31 Dec 20 | 117 | -35 | 88 | 17 |
| 30 Sep 20 | 113 | -34 | 86 | 17 |
| 30 Jun 20 | 113 | -31 | 87 | 23 |
| 31 Mar 20 | 122 | -22 | 89 | 11 |
| 31 Dec 19 | 120 | -13 | 83 | 15 |
| 30 Sep 19 | 116 | -8 | 77 | -1 |
| 30 Jun 19 | 109 | -12 | 73 | -8 |
| 31 Mar 19 | 101 | -16 | 67 | 0 |
| 31 Dec 18 | 92 | -23 | 65 | 15 |
| 30 Sep 18 | 86 | -28 | 63 | 15 |
| 30 Jun 18 | 80 | -31 | 61 | 15 |
| 31 Mar 18 | 76 | -32 | 59 | 14 |
| 31 Dec 17 | 72 | -31 | 55 | 0 |
| 30 Sep 17 | 71 | -27 | 53 | 14 |
| 30 Jun 17 | 72 | -26 | 52 | 15 |
| 31 Mar 17 | 68 | -29 | 52 | 16 |
| 31 Dec 16 | 65 | -31 | 52 | 15 |
| 30 Sep 16 | 61 | -35 | 53 | 15 |
| 30 Jun 16 | 55 | -38 | 52 | 15 |
| 31 Mar 16 | 52 | -36 | 50 | 13 |
| 31 Dec 15 | 50 | -34 | 48 | 13 |
| 30 Sep 15 | 48 | -34 | 48 | 13 |
| 30 Jun 15 | 45 | -33 | 47 | 11 |
| 31 Mar 15 | 42 | -30 | 42 | 10 |
| 31 Dec 14 | 38 | -29 | 39 | 10 |
| 30 Sep 14 | 33 | -27 | 34 | 8 |
| 30 Jun 14 | 29 | -26 | 29 | 8 |
Quality Earnings: VCYT has a large one-off loss of $15.3M impacting its last 12 months of financial results to 31st March, 2025.
Growing Profit Margin: VCYT became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: VCYT has become profitable over the past 5 years, growing earnings by 15.2% per year.
Accelerating Growth: VCYT has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: VCYT has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (21.7%).
Return on Equity
High ROE: VCYT's Return on Equity (2.8%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/20 16:22 |
| End of Day Share Price | 2025/06/20 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Veracyte, Inc. is covered by 20 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sung Ji Nam | BTIG |
| Bryan Brokmeier | Cantor Fitzgerald & Co. |
| William Bonello | Craig-Hallum Capital Group LLC |